Coherus Oncology, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

CHRS$0.82+6.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Exhibit Index

INDEX TO EXHIBITS

· · · · Incorporated by Reference · ·
ExhibitNumber · Description · Form · Exhibit · DateFiled · FiledHerewith
2.1††	Asset Purchase Agreement, by and between Coherus BioSciences, Inc. and Intas Pharmaceuticals Ltd., dated December 2, 2024.	8-K	2.1	12/03/2024

3.1	Amended and Restated Certificate of Incorporation.	8-K	3.1	11/13/2014

3.2	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Coherus BioSciences, Inc., effective as of May 29, 2025	8-K	3.1	5/30/2025

3.3	Second Amended and Restated Bylaws of Coherus Oncology, Inc., effective as of May 29, 2025.	8-K	3.2	5/30/2025

4.1	Reference is made to exhibits 3.1, 3.2 and 3.3.

4.2	Form of Common Stock Certificate.	S-1/A	4.2	10/24/2014

4.3	Indenture, dated as of April 17, 2020, between Coherus Biosciences, Inc. and U.S. Bank National Association, as Trustee.	8-K	4.1	4/17/2020

4.4	Form of certificate representing the 1.5% Convertible Senior Subordinated Notes due 2026.	8-K	4.1	4/17/2020

4.5	Notice of Successor Trustee to Indenture dated February 7, 2022.	10-Q	4.5	5/5/2022

4.6	First Supplemental Indenture, dated March 31, 2025, between Coherus BioSciences, Inc. and U.S. Bank Trust Company, National Association, as trustee.	8-K	4.1	4/1/2025

10.1††#	Letter Agreement between Coherus BioSciences, Inc. and Paul Reider, dated as of May 8, 2025				X

10.2#*	Coherus Oncology, Inc. Amended and Restated 2014 Equity Incentive Award Plan.				X

10.3#*	Coherus Oncology, Inc. 2014 Employee Stock Purchase Plan.				X

10.4#*	Amendment No. 1 to Coherus Oncology, Inc. 2014 Employee Stock Purchase Plan.				X

		Incorporated by Reference
ExhibitNumber	Description	Form	Exhibit	DateFiled	FiledHerewith
10.5#*	Coherus Oncology, Inc. 2016 Employment Commencement Incentive Plan.				X

10.6#*	Executive Change in Control and Severance Plan, effective January 1, 2023.				X

31.1	Certification of Principal Executive Officer Required under Securities Exchange Act Rule 13a-14(a) and 15d-14(a).				X

31.2	Certification of Principal Financial Officer under Securities Exchange Act Rule 13a-14(a) and 15d-14(a).				X

32.1	Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350 and Securities Exchange Act Rule 13a-14(b).				X

101	The following materials from Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 formatted in iXBRL (Inline eXtensible Business Reporting Language) includes: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Comprehensive Income (Loss), (iv) Condensed Consolidated Statements of Stockholders’ Deficit, (v) Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Condensed Consolidated Financial Statements.				X
104	Cover page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101).				X


††	Schedules and attachments to this exhibit have been omitted pursuant to Regulation S-K, Item 601(a)(5).
#	Indicates management contract or compensatory plan.
*	Indicates a compensatory plan that was amended pursuant to a resolution of our Board of Directors solely to effect our name change from Coherus BioSciences, Inc. to Coherus Oncology, Inc.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.